have not yet been reported or are very rare. The applicability of EUCAST expert rules depends on the MIC breakpoints used to define the rules. Setting appropriate clinical breakpoints, based on treating patients and not on the detection of resistance mechanisms, may lead to modification of some expert rules in the future.
Introduction
Antimicrobial susceptibility testing is a daily task in clinical microbiology laboratories worldwide. In view of the increasing complexity and widespread increase in antimicrobial resistance mechanisms and the clinical implications of the resistance, expert knowledge is desirable for interpretation of tests. An expert rule in antimicrobial susceptibility testing describes an action to be taken on the basis of specific antimicrobial susceptibility test results. The rules are based on current clinical breakpoints and knowledge of resistance mechanisms. Expert rules for antimicrobial susceptibility testing can assist clinical microbiologists in the interpretation of antimicrobial susceptibility tests [1] , but with changes in breakpoints and the discovery of new resistance mechanisms, rules may become redundant or require modification. Rules can also contribute to quality assurance by highlighting anomalous or unlikely results [2] [3] [4] [5] . The EUCAST expert rules in antimicrobial susceptibility testing, first published in 2008 (www.eucast.org), are divided into intrinsic resistance, exceptional phenotypes and interpretive rules. In this document we present the second version of these rules which has been updated in line with current EUCAST breakpoints.
Intrinsic resistance
Intrinsic (inherent) resistance, as opposed to acquired and/or mutational resistance, is a characteristic of all or almost all isolates of the bacterial species. The antimicrobial activity of the drug is clinically insufficient or antimicrobial resistance innate, rendering it clinically useless. Antimicrobial susceptibility testing is therefore unnecessary, although it may be done as part of panels of test agents. In these species, "susceptible" results should be viewed with caution, as they most likely indicate an error in identification or susceptibility testing. Even if a susceptible result is confirmed the drug should preferably not be used or, when no alternative is available, it should be used with caution. In some cases, intrinsic resistance to an agent may be expressed at a low-level, with MIC values close to the susceptible breakpoint, although the agent is not considered clinically active. There are also situations where the agent appears fully active in vitro (MIC values cannot be separated from those of the wild type) but is inactive in vivo. These are generally not mentioned in the tables since they are rather a matter of therapeutic recommendations. Examples of intrinsic resistances are Enterobacteriaceae resistant to glycopeptides or linezolid, Proteus mirabilis resistant to nitrofurantoin and colistin, Serratia marcescens resistant to colistin, Stenotrophomonas maltophilia resistant to carbapenems, Grampositive organisms resistant to aztreonam and enterococci resistant to fusidic acid (Tables 1-4) .
Exceptional resistance phenotypes
Exceptional resistance phenotypes are resistances of some bacterial species to particular antimicrobial agents which have not yet been reported or are very rare. Exceptional resistance phenotypes should be checked as they may also indicate an error in identification or susceptibility testing. If they are confirmed locally, the isolate should be further studied to confirm the exceptional phenotype and sent to a reference laboratory or other laboratory with expertise in resistance mechanisms for independent confirmation. Exceptional resistance phenotypes may change as resistance may develop and increase over time. There may also be local, regional or national differences and a very rare resistance in one hospital, area or country may be more common in another. Examples of exceptional phenotypes are Streptococcus pyogenes resistant to penicillin, Staphylococcus aureus resistant to vancomycin, Enterococcus faecium susceptible to ampicillin, Enterobacteriaceae resistant to carbapenems (rare but increasing) and anaerobes resistant to metronidazole (Tables 5-7) .
Interpretive reading and expert rules
Interpretive reading is another type of expert rule and involves inference of resistance mechanisms from susceptibility test results and interpretation of clinical susceptibility on the basis of the resistance mechanism [1] [2] [3] . The applicability of such rules is limited by the range of agents tested, so individual laboratories will need to choose which agents to test for their local requirements. The applicability of any rule will also depend on the MIC breakpoints used to define the rule. EUCAST interpretive rules may be simple, e.g. IF S. aureus is resistant to oxacillin or cefoxitin THEN report resistant to all β-lactams, or more complicated, e.g. IF Enterobacteriaceae are intermediate to tobramycin, resistant to gentamicin and susceptible to amikacin THEN report resistant to tobramycin. The evidence supporting interpretive rules is often not conclusive and there may be differences of opinion regarding the most appropriate clinical action. Hence these rules should be based on current published evidence, the quality of evidence should be assessed and exceptions to any rules should be noted. In the EUCAST tables (tables 8 to 13) the evidence for rules has been graded as follows:
A. There is good clinical evidence that reporting the test result as susceptible leads to clinical failures.
B. Evidence is weak and based on only a few case reports or on experimental models. It is presumed that reporting the test result as susceptible may lead to clinical failures.
C. There is no clinical evidence, but microbiological data suggest that clinical use of the agent should be discouraged. mechanisms not previously recognised and treatment is likely to fail. Comments may also be added to explain actions or warn of resistances of particular epidemiological significance. Advice may be given on further tests that may be appropriate or on the need for referral of isolates to a reference laboratory for checking susceptibility or identification.
Application of EUCAST expert rules may impose some testing requirements on clinical laboratories. Many rules require the full identification of the organism even if it is not essential for clinical management. There may be a need to test an extended range of appropriate agents as interpretive rules may require testing of agents which may not be required clinically. There is also a clinical need for access to a set of expert rules as there are many expert rules and few individuals are able to remember all and to apply them consistently.
There are few publications on expert rules and these are more likely to be used as a reference source than for everyday application [1, 4] . The wide range of expert rules means that they are only likely to be applied consistently and widely if they are available as a published set of rules that can be incorporated into computer systems. Rules may be incorporated into Laboratory Information Systems (LIS) but this is limited by the capabilities of the LIS and the ability and interest of individual laboratories in incorporating rules into the LIS. Expert systems are, however, incorporated into several automated susceptibility and zone reading systems.
The purpose of the EUCAST expert rules is to provide a written description of current expert rules. The rules are a comprehensive collection that may be applied manually or incorporated into automated systems [6, 7] . The rules were prepared by an expert subcommittee in consultation with European national susceptibility breakpoint committees, EUCAST national representatives, the pharmaceutical and susceptibility device manufacturing industries, recognised experts and others via open consultation through the EUCAST website. Rules should not conflict with EUCAST MIC breakpoints, but it is appreciated that some antimicrobial agents are not included in EUCAST breakpoints and many rules have developed over the years in conjunction with other breakpoint systems. Hence rules are likely to be amended as EUCAST breakpoints are developed and in the light of experience with application of the rules and emergence of new resistance mechanisms.
This second version will undoubtedly need to be updated again in the future.
Explanatory notes on EUCAST Expert Rules in Antimicrobial Susceptibility

Testing
The EUCAST Expert Rules Subcommittee was established in 2007 with the objective to assist clinical microbiologists in the interpretation of antimicrobial susceptibility tests beyond interpretation of in vitro tests for the assignment of clinical categories of antimicrobial susceptibility.
For this objective, different rules have been produced, including those defining intrinsic resistances and exceptional phenotypes as well as interpretive rules. The latter are structured in tables (Tables 8-13 of EUCAST Expert rules in Antimicrobial Susceptibility Testing) that group different organisms and/or classes of antimicrobial agents. They were mainly established using EUCAST MIC breakpoints to define the clinical categories (susceptible, intermediate or resistant) included in the expert rule statement. These rules should be applied once the bacterial isolates have been identified to species level. Although recognition of the resistance mechanisms is an essential part of the interpretive expert rule, the final objective is to assist in the clinical use of antimicrobial agents.
Interpretive rules for ß-lactam agents
ß-Lactam compounds are the most widely used antimicrobial agents. They interact with the penicillin binding proteins (PBPs) that are the enzymes involved in the terminal stages of peptidoglycan synthesis and exert a bactericidal effect due to a subsequent imbalance of cell wall autolytic enzymes. Resistance to these compounds is mainly due to ß-lactamases, which are a large family of different hydrolases that disrupt and inactivate the ß-lactam structure. These enzymes variably affect different ß-lactam compounds, thus producing different phenotypes and/or levels of resistance, particularly in Gram-negative bacilli [8, 9] . In addition, target (PBP) modification may also compromise ß-lactam activity. This mechanism is particularly encountered in Gram-positive cocci. The contribution of PBP modification to ß-lactam resistance in Gramnegative organisms is generally less important [10] . Porin modifications and efflux pump hyperexpression in Gram-negative organisms may also compromise ß-lactam compounds, but resistance levels conferred by these mechanisms alone are commonly lower than those observed with resistance conferred by most ß-lactamases [11, 12] . EUCAST expert rules for ß-lactams and Gram-positive cocci are focused on staphylococci, streptococci, including ß-haemolytic isolates, viridans group streptococci, Streptococcus pneumoniae, and enteroccocci (Table 8) .
Staphylococci. Production of penicillinase in staphylococci is very common (>90% of the S. aureus isolates in many countries) and leads to phenotypic resistance to all penicillins except the isoxazolyl analogues (rule 8.2). Staphylococci can also be resistant to the isoxazolyl penicillins due to the production of an abnormal PBP (PBP2a encoded by the mecA gene) leading to cross resistance to all ß-lactams except a few with low affinity to PBP2a (rule 8.1) [13] . Resistance mediated by mecA is commonly referred to as methicillin (or oxacillin) resistance as historically these agents have been widely used for in vitro testing. Detection of methicillin resistance is mandatory in S. aureus clinical isolates [14] . All staphylococci resistant to methicillin, oxacillin and/or cefoxitin, or with positive test for mecA gene or PBP 2a, should be considered resistant to all available ß-lactams [15] with the exception of those specifically licensed to treat infections caused by methicillin-resistant staphylococci. Nevertheless, rare penicillinase hyperproduction may result in borderline resistance to oxacillin (but not cefoxitin) in vitro due to lability of oxacillin but there is no evidence that penicillinase hyperproduction is clinically relevant [16] .
Streptococci. Among ß-haemolytic streptococci, susceptibility to penicillins is currently the rule. No decreased susceptibility to ß-lactams has been reported except in Group B streptococci (MIC of benzylpenicillin up to 1 mg/L) [17] . Isolates susceptible to penicillin can be reported as susceptible to aminopenicillins, cephalosporins and carbapenems [18] . If resistant to penicillin, identification and susceptibility should be checked (rule 8.3). Conversely, resistance to ß-lactams in S. pneumoniae is common due to the production of mosaic PBPs that lead to various patterns of ß-lactam resistance [19] . The oxacillin disk is traditionally used in screening tests to indicate benzylpenicillin susceptibility. Nevertheless, in addition to benzylpenicillin, when clinically needed
MICs of cephalosporins and carbapenems should be determined when the isolate is benzylpenicillin resistant or when the oxacillin disk diffusion screening test is interpreted as resistant (rule 8.4). Among viridans group streptococci, production of mosaic PBPs also leads to various patterns of ß-lactam resistance and the oxacillin disk diffusion test developed for S. pneumoniae shows inadequate sensitivity in prediction of penicillin susceptibility. Moreover, susceptibility to cephalosporins and carbapenems cannot be inferred from benzylpenicillin susceptibility (rule 8.5) [20] .
Enterococci. All enterococci are considered intrinsically resistant to cephalosporins (table 4), but resistance to ampicillin mediated by alterations to PBP5 is increasingly recognized, particularly in E. faecium [21] . These alterations lead to decreased affinity for ß-lactams, including all penicillins and carbapenems (rule 8.6). Penicillinase-producing Enterococcus spp. isolates have been rarely detected, but have recently been described in Europe [22, 23] .
Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. Interpretive reading of the antibiogram is commonly based on ß-lactams and ß-lactamases in Gram-negative bacilli [8] . The first version of EUCAST expert rules for ß-lactams and Enterobacteriaceae was influenced by this, particularly with isolates producing extended-spectrum ß-lactamases (ESBLs) or carbapenemases. Cephalosporin and carbapenem breakpoints available when version 1 of EUCAST expert rules were published were later considered inappropriate and consequently old expert rules addressing ESBL and carbapenemase producers needed to be modified in version 2 of the rules.
For many years confirmatory tests, mainly based on the synergistic effect observed between cephalosporins and ß-lactamase inhibitors such as clavulanate, were applied in clinical microbiology laboratories to indicate the presence of ESBLs, mainly in Escherichia coli and Klebsiella pneumoniae isolates with reduced susceptibility to oxyimino cephalosporins [24] [25] [26] .
Following the detection of ESBL production in an isolate, the susceptible and intermediate categories were reinterpreted as resistant on the assumption that the breakpoints were inadequate. However, some authors claimed that MIC breakpoints set at appropriate levels (decreasing their values) can detect the presence of 'clinically significant' resistance mechanisms, including ESBLs [27] . Animal models, Pk/Pd analysis, Monte Carlo simulation and new lower EUCAST breakpoints supported this approach. It is possible to avoid classification of most ESBL producers as susceptible to oxyimino-cephalosporins (mainly ceftazidime and cefepime) and aztreonam with EUCAST breakpoints when compared with CLSI breakpoints [28, 29] . In addition, reduction in breakpoints so that clinically significant resistance is detected without the need for confirmatory tests avoids possible delay in reporting of susceptibility testing results for a large proportion of isolates as the prevalence of ESBL-producing organisms has increased. Enterobacteriaceae, third and fourth generation cephalosporins should be reported as found and the old expert rule recommending modification of reporting category for ESBL producers that appear susceptible is no longer necessary. This recommendation, that also applies to plasmid mediated AmpC producers, is now included in the EUCAST breakpoint tables. Nevertheless, in many areas ESBL detection and characterization is recommended or mandatory for infection control purposes. For consistency, and based on a similar approach, other rules, including those affecting Klebsiella oxytoca and Citrobacter koseri (old expert rule 9.3) [36] and that for isolates with carbapenemases (old expert rule 9.7), are deleted in version 2 of the expert rules.
Carbapenemases, including class A, B and D enzymes, can have a variable effect on carbapenems [37] [38] [39] . Moreover, combined resistance mechanisms may also affect carbapenem susceptibility (e.g. combination of derepressed AmpC or ESBL and decreased permeability), ertapenem being particularly affected [40] . Recent data, as with ESBLs producers, provide evidence to support reporting of carbapenem susceptibility as found [41, 42] . Nevertheless, more effort is required in the future to expand the evidence, particularly when a carbapenemase with low-level expression, such as with VIM enzymes, is present [43] . It is important to note that special attention should be paid to reduced susceptibility to carbapenems that may be related to true carbapenemases, not only for producers of class B (mainly VIM or IMP) or class A carbapenemases (KPC), but also to those expressing OXA-48, a class D carbapenemase that is increasingly identified in Enterobacteriaceae [44] .
New expert rule number 9.1 highlights the uncertain therapeutic outcome of treatment with a penicillin in combination with a β-lactamase inhibitor for Enterobacteriaceae intermediate or resistant to any third or fourth generation cephalosporin in infections other than those affecting the urinary tract [45, 46] . This is also the case for new expert rule number 9.2, which is evidence graded A for Enterobacter spp. and B for Citrobacter freundii, Serratia spp., Morganella morganii.
Rule 9.2 recommends discouraging use of cefotaxime, ceftriaxone or ceftazidime in monotherapy or suppressing the susceptibility testing results for these agents owing to the risk of selecting resistance in AmpC producers [47] . In some publications it is claimed that this problem can be avoided with combination therapy, including (unlike aminoglycosides) the addition of a fluoroquinolone [48] .
Other Gram-negative organisms. Other Gram-negative organisms, such as Haemophilus influenzae and Neisseria gonorrhoeae are considered in the EUCAST expert rules table 10. For H.
influenzae, resistance to ampicillin, which is considered representative of amoxicillin for susceptibility testing, is mainly due to ß-lactamase production. Isolates producing ß-lactamases, mainly TEM-1, should be considered resistant to both ampicillin and amoxicillin (rules 10.1) [49] .
Ampicillin resistance in the absence of ß-lactamase production can be conferred by mutations in the ftsI gene affecting PBPs and leading to reduced affinity for β-lactams [50] . These isolates, termed β-lactamase negative, ampicillin-resistant (BLNAR), should be considered as resistant to aminopenicillin-ß-lactamase inhibitor combinations (amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam) and to first and second generation cephalosporins (rule 10.2) [51, 52] .
Although piperacillin and piperacillin-tazobactam appear less affected by the PBP-mediated resistance mechanisms, evidence regarding clinical efficacy is lacking.
H. influenzae isolates with altered PBPs and ß-lactamase production are also increasingly found. These isolates are phenotypically resistant to amoxicillin-clavulanate and ampicillinsulbactam (ß-lactamase positive and resistant to amoxicillin-clavulanate, BLPACR) and should also be considered resistant to piperacillin-tazobactam and to first and second generation cephalosporins (rule10.3) [53] . ESBL-producing isolates have not yet been found in H. influenzae but bla ESBL genes have been cloned in this species resulting in third generation cephalosporin resistance when PBP 3 is concomitantly altered [54] . Moreover, a TEM ESBL variant has also been found in Haemophilus parainfluenzae [55] .
For Neisseria gonorrhoeae, isolates that are ß-lactamase positive should be considered resistant to benzylpenicillin, ampicillin and amoxicillin. Chromosomal mutations affecting affinity of PBPs, decreased permeability or efflux pumps also confer resistance to ß-lactamase inhibitor combinations and resistance will be detected by the application of EUCAST breakpoints (rule 10.4) [56] [57] [58] .
Expert rules for Moraxella catarrhalis have been deleted in version 2 of the expert rules and the relevant points are now included in the breakpoint table.
Interpretive rules for macrolides, lincosamides and streptogramins
Although the macrolides, lincosamides and streptogramins have different chemical structures, they share similar mechanisms of action and can be affected by the same resistance mechanisms.
EUCAST expert rules for these agents include staphylococci, streptococci, Peptostreptococcus spp., and Bacteroides spp. (Table 11 , rules 11.1 to 11.5). Other organisms, such as H. influenzae, have been considered in this version of the expert rules only within the intrinsic resistance tables.
Erythromycin is considered the class representative for 14-(clarithromycin) and 15-membered (azithromycin) ring macrolides, with the exception of ketolides (telithromycin).
Resistance to these compounds is generally mediated by the production of ribosomal methylases encoded by erm genes that confer constitutive or inducible macrolide-lincosamide-streptogramin B (MLS B ) phenotypes or by the production of an efflux pump (M phenotype, conferring resistance to erythromycin but not clindamycin and/or streptogramins) [59] . With both mechanisms there is cross-resistance between erythromycin and the other 14-and 15-membered ring macrolides (rule 11.1). This resistance can be with or without cross-resistance to clindamycin and lincosamides. In staphylococci and streptococci, isolates resistant to erythromycin but susceptible to clindamycin should be tested for inducible MLS B resistance (dissociated resistance) [59] . [60] . In staphylococci, isolates that are simultaneously resistant to erythromycin and clindamycin or lincomycin, a warning of reduced susceptibility to the combination quinupristin-dalfopristin and loss of bactericidal activity should be included in the susceptibility test report (rule 11.5) [61, 62] .
In streptococci, less clinical evidence is available but, similarly, isolates that are resistant to erythromycin and susceptible to clindamycin should be tested for inducible MLS B resistance and reported as clindamycin susceptible if positive but with a warning that resistance may develop on prolonged treatment (rule 11.3) [59] . When Peptostreptococcus spp. and Bacteroides spp. express inducible MLS B phenotype, resistance to clindamycin is difficult to detect in vitro and this agent should not be considered to be clinically active (rule 11.4) [63, 64] .
Interpretive rules for aminoglycosides
Aminoglycoside agents have a bactericidal effect on most Gram-positive and Gram-negative organisms. They bind to 16S rRNA of the 30S bacterial ribosomal subunit and thereby inhibit protein synthesis. Several mechanisms that compromise the activity of aminoglycosides have been described: a) decreased permeability and/or accumulation of the aminoglycoside agents due to mutations affecting passive diffusion or active transport, porin and/or lipopolysaccharide alteration (only in Gram-negatives), and efflux pump hyper-expression; b) target (ribosomal) modifications due to mutations in ribosomal proteins (S3, S4, S5, S6, S12, S17, and L6) and as a result of the action of new methylases affecting 16S RNA; and c) aminoglycoside modifying enzymes that are acetyltransferases, phosphotransferases or nucleotidyltransferases (also known as adenylyltransferases) [65] [66] [67] [68] [69] .
Phenotype recognition of these resistance mechanisms is generally more complex than those affecting ß-lactam compounds. Decreased permeability and/or resistance mechanisms involving efflux pumps usually confer a low-level resistance phenotype affecting nearly all aminoglycosides. With the exception of those described in P. aeruginosa, resistance mediated by efflux pumps is difficult to infer from phenotypic susceptibility [69] ; but cross-resistance to other antimicrobial classes such as fluoroquinolone or tetracycline agents might indicate their potential presence. Ribosomal mutations are extremely rare, do not confer 'class resistance' and do not always endow high-level resistance. Conversely, 16S RNA methylation confers high-level resistance, mainly affecting 4,6-disubstituted compounds (such as kanamycin, gentamicin, tobramycin, amikacin and netilmicin), but not 4,5-disubstituted compounds (such as neomycin or paramomycin), streptomycin and/or the aminocyclitol agent spectinomycin [70] .
Aminoglycoside modifying enzymes are the most widely distributed resistance mechanisms affecting aminoglycosides and enzymatic modification of an aminoglycoside can be mediated by different enzymes. Modifications do not always confer phenotypic resistance and resistance may be more clearly indicated in tests with aminoglycoside agents not used in the human clinical setting [70] [71] [72] [73] . Other problems complicating interpretive reading of this group of antimicrobials are that the enzymatic modification of different aminoglycosides can be produced by a single enzyme and that unrelated enzymes can confer a similar resistance phenotype. Also a single isolate can express different modifying enzymes, making interpretation of resistance phenotypes difficult and in some cases unreliable.
Despite this apparent complexity, several EUCAST interpretive rules can be applied when reading antibiograms of aminoglycosides (Table 12 ). In Gram-positive organisms, these rules facilitate detection of the absence of synergy between a specific aminoglycoside and ß-lactam or glycopeptide agents (rules 12.1 to 12.6). In enterococci, the evidence for these rules is graded A or B and is based on clinical data [74, 75] . In staphylococci, however, the evidence for most rules is graded C due to microbiological demonstration of the absence of in vitro synergy of the aminoglycosides with cell wall active compounds even with isolates that are apparently susceptible to aminoglycosides [76, 77] .
In Gram-negative organisms, EUCAST interpretive rules for aminoglycosides tend to change a susceptible or an intermediate result to the resistant category (rules 12.7 to 12.10). The evidence for all of these rules is graded C and is mainly based on biochemical data indicating that these compounds are enzymatically affected. In most cases, the increase in MIC values or decrease in inhibition zones is very small. Modification of results to the resistant category avoids clinical use of these compounds [78] [79] [80] [81] .
In certain Gram-negatives, such as Providencia stuartii (but not Providencia rettgerii) and Serratia marcescens, the aminoglycoside modifying enzymes are chromosomally encoded and are weakly expressed. However, as mutational events confer phenotypic resistance, these isolates should be considered as (intrinsically) resistant to these agents (Table 1, rules 1.12 and 1.14) [82] [83] [84] . E. faecium intrinsically produces a chromosomal aminoglycoside modifying enzyme that is also responsible for loss of synergy between certain aminoglycosides and cell wall active compounds (Table 4 , rule 4.8) [85] .
Interpretive rules for quinolones
The quinolone agents are rapidly bactericidal within a range of concentrations and when that range is exceeded the lethal action is diminished [86] . The quinolones interact with bacterial type II topoisomerases DNA gyrases encoded by genes gyrA and gyrB and topoisomerase IV encoded by parC and parE (in staphylococci grlA and grlB), being the preferential targets of Gram-negative and Gram-positive organisms, respectively. Topoisomerase mutations in gyrA and parC genes and reduction in target access, including porin modification and efflux systems, are the classical chromosomally encoded mechanisms affecting these compounds. Topoisomerase mutations can confer high level resistance, mainly due to stepwise selection of several mutations in the same or different topoisomerase [87] .
Plasmid-mediated quinolone resistance mechanisms have emerged in Gram-negative bacilli during the last decades, and are now frequently observed in many parts of the world [88] . All of them demonstrate low expression and do not always affect all fluoroquinolone agents. Target protection mechanisms due to the Qnr proteins were the first described plasmid mediated resistance mechanisms [89] . Several families of these proteins have now been described, mainly in Enterobacteriaceae. In addition, enzymatic modification due to a mutated aminoglycoside modifying enzyme and also affecting only certain fluoroquinolones has been identified in these organisms. This enzyme [AAC(6')-Ib-cr] affects C7-piperazinyl substituted fluoroquinolones, ciprofloxacin and norfloxacin, but not levofloxacin [90] . More recently, two plasmid-mediated effluxbased mechanisms involving the QepA and OqxAB pumps related to major facilitator superfamily (MFS) transporters were described. In this case the resistance is low-level and phenotypic detection is extremely difficult [91, 92] .
In general, older quinolones have lower activity than more recently developed agents. This is more obvious with Gram-negative organisms and is particularly evident in Enterobacteriaceae.
However, particularly with resistance due to mutations in topoisomerases, decreased susceptibility to one fluoroquinolone is reflected in reduced susceptibility to other fluoroquinolones (class resistance). With these isolates, the concomitant presence of different mutations increases the level of fluoroquinolone resistance. Nevertheless, Qnr proteins, efflux and enzymatic modification resistance mechanisms may not confer resistance to all fluoroquinolones. Such low-level resistance mechanisms are difficult to detect but they indicate the potential for selection of higherlevel resistance mechanisms.
When reading antibiograms with quinolones, resistance to the most active fluoroquinolone in vitro indicates resistance to all fluoroquinolones in both Gram-negative and Gram-positive organisms [93] [94] [95] . An exception to this rule in Gram-negatives is the potential production of the AAC(6')-Ib-cr enzyme that affects ciprofloxacin but not levofloxacin EUCAST interpretive rules for fluoroquinolones (rules 13.2, 13.4, 13.5, 13.6, and 13.8) all take this approach, supported by different levels of evidence (grades B or C). In some organisms (i.e. Enterobacteriaceae and H. influenzae), nalidixic acid can be used as a predictor of resistance mechanisms affecting fluoroquinolones [96] [97] [98] . However, in Enterobacteriaceae this compound does not detect qnr-or other plasmid-mediated quinolone resistance, which is increasingly recognized all over the world. In staphylococci and viridans group streptococci, resistance to the less active, but not to the more active fluoroquinolones, indicates that a first step mutation may be present. In this case, a warning should be added to the susceptibility testing report alerting clinicians to the potential for selection of a higher-level resistance mechanism involving different mutations (rules 13.1 and
13.3).
Inference of specific fluoroquinolone resistance mechanisms can be difficult in multidrugresistant organisms as they may have superimposed mechanisms affecting these compounds (low-and/or high-level resistance). Moreover, with any of the new plasmid mediated resistance mechanisms there is little possibility for interpretive reading. In some cases, a slight decrease in susceptibility to all quinolones is observed, but in others a greater decrease in susceptibility to fluoroquinolones than that observed with nalidixic acid can be seen [90] [91] [92] . Finally, it is necessary to stress that clinical breakpoints, as defined by EUCAST, do not aim to detect all resistance mechanisms that might be present in the bacteria. Rather, they have been developed to predict the outcome of antimicrobial treatment of infected patients based on microbiological, Pk/Pd and clinical criteria. It is also important to note that EUCAST expert rules should be used with EUCAST breakpoints and may not be applicable if other breakpoint systems are used.
Future of expert rules and concluding remarks
Transparency declarations
Nothing to declare
Funding support
EUCAST is supported by a grant from the ECDC and by ESCMID. Enterobacter cloacae R R R R 1. 4 Enterobacter aerogenes R R R R 1.5
Escherichia hermannii R R 1. 6 Hafnia alvei R R R 1.7
Klebsiella spp.
Proteus mirabilis R R R 1. 10 Proteus vulgaris
Yersinia pseudotuberculosis R R = resistant 1 Azithromycin is effective in vivo for the treatment of typhoid fever and erythromycin may be used to treat travellers' diarrhoea. 2 Providencia stuartii produces a chromosomal AAC(2')-Ia enzyme and should be considered resistant to clinically available aminoglycosides except amikacin, arbekacin and streptomycin. Some isolates express the enzyme poorly and can appear susceptible to netilmicin in vitro, but should be reported as resistant as mutation can result in overproduction of this enzyme. 3 All Serratia marcescens produce a chromosomal AAC(6')-Ic enzyme that affects the activity of clinically available aminoglycosides except streptomycin, gentamicin and arbekacin. 1 Acinetobacter baumannii may appear susceptible to ampicillin-sulbactam due to activity of sulbactam against this species.
2 Burkholderia cepacia complex includes different species. Some strains may appear susceptible to some β-lactams in vitro but they are clinically resistant and are shown as R in the table. 3 Burkholderia cepacia and Stenotrophomonas maltophilia are intrinsically resistant to all aminoglycosides. Intrinsic resistance is attributed to poor permeability and putative efflux. In addition, most Stenotrophomonas maltophilia produce the AAC(6')Iz enzyme. 4 Pseudomonas aeruginosa is intrinsically resistant to kanamycin and neomycin due to low level APH(3')-IIb activity. Clostridium ramosum, Clostridium innocuum R R = resistant; 1 Low-level resistance (LLR) to aminoglycosides. Combinations of aminoglycosides with cell wall inhibitors (penicillins and glycopeptides) are synergistic and bactericidal against isolates that are susceptible to cell wall inhibitors and do not display high-level resistance to aminoglycosides. 2 In addition to LLR to aminoglycosides, Enterococcus faecium produces a chromosomal AAC(6') enzyme that is responsible for the loss of synergism between aminoglycosides (except gentamicin, amikacin, arbekacin and streptomycin) and penicillins or glycopeptides. 
5.2
Serratia marcescens, Proteae Susceptible to colistin.
5.3
Pseudomonas aeruginosa and Acinetobacter spp. Resistant to colistin.
Haemophilus influenza
Resistant to any third-generation cephalosporin, carbapenems, fluoroquinolones.
Moraxella catarrhalis
Resistant to ciprofloxacin, any third-generation cephalosporin.
Neisseria meningitides
Resistant to any third generation cephalosporins, fluoroquinolones.
Neisseria gonorrhoeae
Resistant to third-generation cephalosporins, spectinomycin.
1
Except in countries in which carbapenemase-producing Enterobacteriaceae are not rare. 
Streptococcus pneumoniae
Resistant to imipenem, meropenem, vancomycin, teicoplanin, linezolid, quinupristindalfopristin, daptomycin, tigecycline, rifampicin.
6.5
Group A, B, C and G β-haemolytic streptococci Resistant to penicillin, cephalosporins, vancomycin, teicoplanin, linezolid, quinupristin-dalfopristin, daptomycin, tigecycline.
6.6
Enterococcus spp. Resistant to linezolid, daptomycin, tigecycline. Resistant to teicoplanin but not vancomycin.
Enterococcus faecalis, Enterococcus gallinarum, Enterococcus casseliflavus, Enterococcus avium
Susceptible to quinupristin-dalfopristin. Consider likelihood of misidentification. If also resistant to ampicillin it is almost certainly E. faecium.
Enterococcus faecium
Resistant to quinupristin-dalfopristin. Consider likelihood of misidentification, especially if also susceptible to ampicillin. 1 Except in countries where linezolid or quinupristin-dalfopristin resistant coagulase-negative staphylococci are not rare. Resistance to kanamycin is generally due to the production of APH(3')I-3, ANT(4')(4'')-I or bifunctional APH(2')- C [124] 
